The immune system fucntion is tightly regulated by co-inhibitory and co-stimulatory receptors expressed on immune cells or tissues. Antagonistic antibodies dominate antibody drug discovery though inhibiting negative immune checkpoints and reverse immune resistance of tumors. Based on advanced technologie and well-estabished reputatation in the antibody development field, Creative Biolabs has launched a broad range of proven antibody discovery, engineering, and production techniques for global clients. Notably, we’re a preferred and trusted supplier to produce modified antagonistic antibodies against a panel of co-inhibitory receptors by offering custom antibody engineering services.
Antagonistic antibodies have become an effective therapeutic option for several diseases and malignant cances. Since their promising efficacy in clinic, it is of particular interest to develop antagonistic antibodies during drug competition. In efforts to gain a competitive advantage and significant benefits to patients, innovations in antibody engineering have sought to improve the pharmacokinetic properties and maxmize the potentcy of antagonistic agents. For example, symmetric engineered Fc, asymmetric engineered Fc, and afucosylated Fc are reported to increase antibody-dependent cellular cytotoxicity (ADCC) activity. Also, Fc engineering to promote the antibody hexamerization is able to enhance the complement-dependent cytotoxicity (CDC) activity.
Fig.1 TNFR2 conformational epitopes of dominant TNFR2 antagonists. (Torrey, 2017)
Antagonistic antibody engineering describes the generation of human antibodies using in vivo or in vitro techniques for basic research or clinical use. Where the specific situation is known, engineered antibodies can work through antagonistic action by hindering an interaction between themselves and their ligands. Therapeutic antagonist drugs have revolutionized the treatment of human diseases, and a number of antagonistic antibodies acting on repressors under research and development involving anti-CD47, anti-PD-1, anti-PD-L1 (B7-H1), anti-CTLA-4, anti-KIR, and anti-TGF-β.
Antagonistic antibodies are derived from the immune system’s adaptive arm to defend the organism from pathogens and malignant tumors. These antibodies exert their functions to promote health and the current novel treatments based on them might be extremely curative. Recent developments in antibody engineering construct therapeutic antagonistic antibodies that are safer, more efficacious, and more convenient in clinical applications. At Creative Biolabs, antagonistic antibodies can be constructed after early screening and our experts have employed many different engineering strategies to optimize antibody’s activity, including but not limited to:
In addition, we provide popular Antagonistic Antibody Characterization and Antagonistic Antibody Screening Services, which respectively help customers to characterize the properties of antagonist antibodies by ELISA, MS, HPLC, etc., as well as to identify potential antagonist candidates targeting a specific target by phage display, yeast display, hybridoma technology, and so on.
As a leading company in custom antibody development services, Creative Biolabs strives to deliver specialized support in antagonistic antibody design, modification, and evaluation through the state-of-the-art antibody engineering platforms. For more information, please feel free to contact us or directly send us an online inquiry.